Anatara Lifesciences Ltd (AU:ANR) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Anatara Lifesciences Ltd has announced a change in the interests of director David Brookes, as required by listing rules and the Corporations Act. Brookes has made indirect acquisitions through Tarandi 1996 Pty Ltd and Dahlbrook Family Trust, purchasing 750,000 ordinary shares each, totaling a value of $60,000. No options were disposed of, and the number of securities held prior to the change included over 3 million ordinary shares and more than 1.6 million options across direct and indirect holdings.
For further insights into AU:ANR stock, check out TipRanks’ Stock Analysis page.